Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 293

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 293
---
 Business Innovation Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration 168 with leading academic centers and continues to support development of CogniMIR ®, DiamiR’s lead diagnostic product candidate for early detection and monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ -enrichedmicroRNAs as biomarkers of Rett Syndrome.” The accompanying consolidated financial statements have been prepared assuming that DiamiR will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might be necessary if DiamiR is unable to continue as a going concern. Recent Events In May 2025, DiamiR entered into a fee -for -serviceagreement to perform exploratory blood biomarker testing for a life sciences company developing therapeutic agent for AD. In May 2025, DiamiR was successfully renewed its CT State and CLIA licenses after an inspection of its New Haven CT laboratory by State inspectors. In April 2025, DiamiR launched its microRNA testing services and updated its website to advertise this service to prospective biopharma customers. In April 2025, DiamiR successfully passed its CAP inspection and was granted a 2 -yearextension on its CAP accreditation until 2027. In April 2025 and June 2025, DiamiR amended the convertible note with Kira Sheinerman, one of its founders and the Executive Director, such that the founder loaned DiamiR additional $100,000 or $150,000, respectively. Financial Operations Overview Revenue In 2010, DiamiR began the process of developing CogniMIR ®. To date, DiamiR has primarily earned revenue from grants and have not generated any product revenue other than revenues from research testing services for third parties and other revenue generated for performing laboratory services DiamiR previously provided to Interpace Biosciences, Inc. (“Interpace”). DiamiR’s ability to generate product revenue, which it does not expect to occur until at least second half 2025, if ever, will depend heavily on DiamiR’s ability to comply with regulatory requirements for, and to commercialize successfully, CogniMIR ®and